Sumatriptan: here's the fair price
This is what US pharmacies pay, on average, for sumatriptan. Use it to spot a fair cash price, and feel good about asking for one.
Sumatriptan Succ 25 Mg Tablet
A fair cash price is usually this cost plus a dispensing fee. If your quote is many times higher, ask about a generic, another pharmacy, or a cash discount.
Ask for generic Sumatriptan Succ 25 Mg Tablet. Pharmacies pay about $7.60 for 30. Ask your pharmacy for its cash price and compare it with your copay. A fair cash price is close to this cost plus a dispensing fee.
Source: CMS NADAC as of 2026-11-04. Ask your prescriber or pharmacist whether a generic is right for you.
Source: CMS NADAC weekly file as of 2026-11-04. Median across NDCs with the same description. Public domain.
Your ZIP and location stay in your browser. We never store them.
Every strength and form
| Product | Pharmacy cost | 30 count | Effective |
|---|---|---|---|
| SUMATRIPTAN SUCC 25 MG TABLETGeneric | $0.25 per tablet or capsule | $7.60 | 10/21/2026 |
| SUMATRIPTAN SUCC 50 MG TABLETGeneric | $0.31 per tablet or capsule | $9.38 | 10/21/2026 |
| SUMATRIPTAN SUCC 100 MG TABLETGeneric | $0.44 per tablet or capsule | $13.13 | 10/21/2026 |
| SUMATRIPTAN 6 MG/0.5 ML VIALGeneric | $14.38 per mL | n/a | 10/21/2026 |
| SUMATRIPTAN 20 MG NASAL SPRAYGeneric | $15.63 per tablet or capsule | $468.94 | 10/21/2026 |
| SUMATRIPTAN 5 MG NASAL SPRAYGeneric | $18.05 per tablet or capsule | $541.37 | 10/21/2026 |
| SUMATRIPTAN 6 MG/0.5 ML AUTOINJGeneric | $59.41 per mL | n/a | 10/21/2026 |
Source: CMS NADAC, as of 2026-11-04. National average acquisition cost, not a retail quote.
Label basics
What it is used for (FDA label)
1 INDICATIONS AND USAGE Sumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: • Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine attack treated with Sumatriptan Injection reconsider the diagnosis before Sumatriptan Injection is administered to treat any subsequent attacks. • Sumatriptan Injection is not indicated for the prevention of migraine attacks or cluster headache attacks. Sumatriptan injection, USP is a serotonin (5-HT 1B/1D ) receptor agonist (triptan) indicated for: •...
Common side effects (FDA label)
6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in the labeling: · Myocardial ischemia, myocardial infarction, and Prinzmetal’s angina [see Warnings and Precautions (5.1)] · Arrhythmias [see Warnings and Precautions (5.2)] · Chest, throat, neck, and/or jaw pain/tightness/pressure [see Warnings and Precautions (5.3)] · Cerebrovascular events [see Warnings and Precautions (5.4)] · Other vasospasm reactions [see Warnings and Precautions (5.5)] · Medication overuse headache [see Warnings and Precautions (5.6)] · Serotonin syndrome [see Warnings and...
Drug interactions (from the label)
7 DRUG INTERACTIONS 7.1 Ergot-Containing Drugs Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan injection within 24 hours of each other is contraindicated. 7.2 Monoamine Oxidase-A Inhibitors MAO-A inhibitors increase systemic exposure by 2-fold. Therefore, the use of Sumatriptan injection in patients receiving MAO-A inhibitors is contraindicated [see Clinical Pharmacology (12.3)]. 7.3 Other 5-HT 1 Agonists Because their vasospastic effects may be additive, coadministration of Sumatriptan injection and other...
Warnings (from the label)
5 WARNINGS AND PRECAUTIONS • Myocardial ischemia/infarction and Prinzmetal’s angina: Perform cardiac evaluation in patients with multiple cardiovascular risk factors (5.1) • Arrhythmias: Discontinue Sumatriptan Injection if occurs (5.2) • Chest/throat/neck/jaw pain, tightness, pressure, or heaviness: Generally not associated with myocardial ischemia; evaluate for coronary artery disease in patients at high risk (5.3) • Cerebral hemorrhage, subarachnoid hemorrhage, and stroke: Discontinue Sumatriptan Injection if occurs (5.4) • Gastrointestinal ischemic reactions and peripheral vasospastic reactions: Discontinue Sumatriptan Injection if occurs (5.5) • Medication overuse headache:...
Source: FDA drug label via openFDA, label effective 2024-09-28. Full label on DailyMed. Excerpts are verbatim and truncated. Read the full label and ask your pharmacist.